KORRO BIO INC (KRRO) Stock Price, Forecast & Analysis
USA - NASDAQ:KRRO - US5009461089 - Common Stock
KRRO Key Statistics, Chart & Performance
The current stock price of KRRO is 6.0119 USD. In the past month the price decreased by -86.73%. In the past year, price decreased by -88.24%.
KRRO Latest News, Press Relases and Analysis
KRRO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.81 | 414.20B | ||
| AMGN | AMGEN INC | 15.58 | 183.47B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 154.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.03 | 111.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.6 | 74.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 908.29 | 60.72B | ||
| INSM | INSMED INC | N/A | 41.61B | ||
| NTRA | NATERA INC | N/A | 28.26B | ||
| BIIB | BIOGEN INC | 9.8 | 24.04B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 21.44B | ||
| INCY | INCYTE CORP | 16.47 | 20.65B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.41 | 14.27B |
Related stock screener links
About KRRO
Company Profile
Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company is headquartered in Cambridge, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2019-10-03. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Company Info
KORRO BIO INC
One Kendall Square. Building 600-700, Suite 6-401
Cambridge MASSACHUSETTS US
Employees: 92
Phone: 16174681999
KORRO BIO INC / KRRO FAQ
What does KRRO do?
Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company is headquartered in Cambridge, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2019-10-03. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
What is the current price of KRRO stock?
The current stock price of KRRO is 6.0119 USD. The price decreased by -2.25% in the last trading session.
Does KRRO stock pay dividends?
KRRO does not pay a dividend.
How is the ChartMill rating for KORRO BIO INC?
KRRO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does KORRO BIO INC have?
KORRO BIO INC (KRRO) currently has 92 employees.
What is the Short Interest ratio of KORRO BIO INC (KRRO) stock?
The outstanding short interest for KORRO BIO INC (KRRO) is 13.23% of its float.
KRRO Technical Analysis
KRRO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KRRO. While KRRO has a great health rating, there are worries on its profitability.
KRRO Financial Highlights
Over the last trailing twelve months KRRO reported a non-GAAP Earnings per Share(EPS) of -9.75. The EPS increased by 78.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.63% | ||
| ROE | -79.37% | ||
| Debt/Equity | 0 |
KRRO Forecast & Estimates
15 analysts have analysed KRRO and the average price target is 95.75 USD. This implies a price increase of 1492.72% is expected in the next year compared to the current price of 6.0119.